Last $179.67 USD
Change Today +1.48 / 0.83%
Volume 3.0M
AGN On Other Exchanges
New York
As of 8:04 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

allergan inc (AGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/29/14 - $181.94
52 Week Low
11/7/13 - $88.34
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ALLERGAN INC (AGN)

allergan inc (AGN) Details

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders; and facial aesthetics products. The company also holds LiRIS Program, which is in Phase II trials for the treatment of interstitial cystitis/bladder pain syndrome. It sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. The company focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, urologists, urogynecologists, and general practitioners. It has collaboration agreements with Molecular Partners AG; Spectrum Pharmaceuticals, Inc.; and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.

11,700 Employees
Last Reported Date: 08/5/14
Founded in 1948

allergan inc (AGN) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.4M
Total Annual Compensation: $651.9K
Corporate Vice President and President of Nor...
Total Annual Compensation: $550.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $642.1K
Non-Executive Officer
Total Annual Compensation: $641.5K
Compensation as of Fiscal Year 2013.

allergan inc (AGN) Key Developments

Allergan, Inc. Receives Approval from U.S. Food and Drug Administration for OZURDEX

Allergan Inc. announced that the U.S. Food and Drug Administration has approved OZURDEX (dexamethasone intravitreal implant) 0.7 mg, a sustained-release biodegradable steroid implant, for the treatment of diabetic macular edema (DME). OZURDEX was originally approved in June as a treatment for DME in adult patients who have an artificial lens implant (pseudophakic) or who are scheduled for cataract surgery (phakic). Based on ongoing review of clinical data demonstrating efficacy and safety, the FDA has now approved OZURDEX for use in the general DME patient population. The FDA approval of OZURDEX is based on the MEAD (Macular Edema: Assessment of Implantable Dexamethasone in Diabetes) study where OZURDEX has demonstrated long-term efficacy in the treatment of DME without the need for monthly injections. MEAD includes two multi-center 3-year sham-controlled, masked, randomized clinical studies assessing the proportion of patients with 15 or more letters improvement in best-corrected visual acuity (BCVA) from baseline. The most common adverse events in the studies included cataracts and elevated intraocular pressure (IOP). An increase in mean IOP was seen with each treatment cycle, and the mean IOP generally returned to baseline between treatment cycles. The OZURDEX implant is also indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) and for the treatment of non-infectious uveitis affecting the posterior segment of the eye.

Allergan to Reportedly Buy Salix For $12 Billion

As per various press reports, Allergan Inc. (NYSE:AGN) may be imminently planning an acquisition of Salix Pharmaceuticals Ltd. (NasdaqGS:SLXP) for over $12 billion in cash.

Allergan Reportedly In Buyout Talks With Salix

Actavis plc (NYSE:ACT) is in buyout talks with Salix Pharmaceuticals Ltd. (NasdaqGS:SLXP), CNBC reported. Allergan Inc. (NYSE:AGN) has also been in talks with Salix as it tries to fend off an unwanted bid from Valeant Pharmaceuticals International, Inc. (TSX:VRX). Valeant said that such concerns were "completely unfounded." "In the third quarter, we expect our results to be better than consensus on revenue, and better than the guidance we provided in our second quarter earnings call for Cash EPS, organic growth, restructuring charges and adjusted cash flow from operations," Michael Pearson, Chief Executive Officer of Valeant said in a letter to Allergan's Board.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGN:US $179.67 USD +1.48

AGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $238.48 USD -2.80
Astellas Pharma Inc ¥1,592 JPY -42.00
Regeneron Pharmaceuticals Inc $355.61 USD -4.91
Shire PLC 5,315 GBp +5.00
Sun Pharmaceutical Industries Ltd 860.80 INR 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation AGN Industry Range
Price/Earnings 40.8x
Price/Sales 7.9x
Price/Book 7.8x
Price/Cash Flow 37.8x
TEV/Sales 7.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGAN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at